|Bid||218.23 x 800|
|Ask||218.38 x 800|
|Day's range||217.17 - 219.38|
|52-week range||189.40 - 253.67|
|Beta (5Y monthly)||0.47|
|PE ratio (TTM)||39.82|
|Earnings date||26 Apr 2023 - 01 May 2023|
|Forward dividend & yield||1.76 (0.82%)|
|Ex-dividend date||08 Feb 2023|
|1y target est||257.57|
ResMed to conduct an internal search for a successor general counselAmy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023. ResMed will c
U.S. stock markets are going through an unusually volatile period, thanks to the uncertainty posed by the global banking crisis and the Federal Reserve's plan for interest rates. While wild price swings can be nerve-racking for shareholders, choppy markets can also be a great time to pick up shares of top companies at significant discounts to their intrinsic value. Which growth stocks are on watch for a possible entry point?
Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.